Gastroesophageal Junction Adenocarcinoma
Gastroesophageal junction adenocarcinoma is a type of cancer that occurs where the esophagus meets the stomach, often leading to symptoms like difficulty swallowing, weight loss, and chest pain.
HER2+ Cancer Treatment: Zongertinib Study
We are exploring the safety and effectiveness of zongertinib, alone and with other treatments, for patients with advanced HER2+ metastatic breast and gastric cancers. This study aims to find the best dose and understand how it may help manage these cancers.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Esophageal Adenocarcinoma
Esophageal adenocarcinoma is a cancer that forms in the lining of the esophagus, which can cause symptoms such as difficulty swallowing, persistent cough, and chest pain.
Metastatic Breast Cancer
Metastatic breast cancer occurs when breast cancer spreads to other parts of the body, leading to symptoms like bone pain, swelling, and fatigue.
Metastatic Gastric Adenocarcinoma
Metastatic gastric adenocarcinoma is a type of stomach cancer that has spread to other areas, often causing symptoms like abdominal pain, nausea, and loss of appetite.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 18 years old or older?
- Do you have HER2 positive metastatic breast cancer (mBC) or metastatic gastric or gastroesophageal adenocarcinoma (mGEAC)?
- Do you have any heart problems, such as heart failure or a history of arrhythmias?
- Have you had any lung problems that required steroids or are you currently experiencing lung issues?
- Is your heart's pumping ability (ejection fraction) 50% or higher?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Enhertu
Kadcyla
BI 1810631
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Capecel
Capecitabin Al
Capecitabin Amarox
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Leuven
Medical Oncology
Heverlee, Belgium
Hopital De Libramont
Oncology
Neufchâteau, Belgium
Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur
Oncology
Saint-Servais, Belgium
Sponsor: Boehringer Ingelheim International GmbH
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.